Research Library
Curated Studies & Clinical Data
A growing library of peer-reviewed studies, clinical trial data, and systematic reviews organized by compound. Every citation is linked to its primary source.
Beyond weight loss: a narrative review of tirzepatide’s impact on muscle and lean mass in people with overweight and obesity
Current medical research and opinion, 2026;:1-12
Semaglutide for Treating Paediatric Craniopharyngioma-Related Obesity: A Multicentre Case Series
Diabetes, obesity & metabolism, 2026
Indirect comparative efficacy and safety of tirzepatide vs semaglutide for the treatment of obesity or overweight in patients without type 2 diabetes
International journal of obesity (2005), 2026
The dual incretin agonist tirzepatide blunts nicotine-induced behaviours and neurochemistry in male mice
British journal of pharmacology, 2026
Chronic semaglutide treatment attenuates cue-induced reinstatement of cocaine-seeking and cocaine-induced stereotypy in male and female rats
bioRxiv : the preprint server for biology, 2026
Divergent ocular safety profiles of glucagon-like peptide-1 receptor agonists: a pharmacological heterogeneity framework
Frontiers in medicine, 2026;13:1957367
Pancreatic and biliary safety signals of GLP-1 receptor agonists and tirzepatide: a disproportionality analysis of FAERS reports
Frontiers in endocrinology, 2026;17:1941948
Cardiometabolic therapy for rhythm control: a case report of refractory atrial fibrillation resolving after initiation of semaglutide for obesity
European heart journal. Case reports, 2026;10(10):ytag727
Reproductive and Gynecologic Effects of Glucagon-Like Peptide-1 Receptor Agonists in Women With Polycystic Ovary Syndrome: A Scoping Review
Cureus, 2026;18(9):e117072
Hypothalamic obesity in pediatric vs. adult craniopharyngioma: mechanisms, management, and cardiometabolic outcomes
Pituitary, 2026;29(5)
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Melanoma and Nonmelanoma Skin Cancer: A Propensity Score-Matched Cohort Study
Diabetes, obesity & metabolism, 2026
Effectiveness of Adding GLP-1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study
Diabetes, obesity & metabolism, 2026
Impact of Glucagon-Like Peptide 1 (GLP-1) and Gastric Inhibitory Polypeptide (GIP) Receptor Agonists on Intraocular Pressure in Glaucoma: A Case Series
Journal of ophthalmology and advance research, 2026;7(3)
GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks
Drugs, 2026
Renal AA amyloidosis associated with severe obesity: improvement in kidney function and proteinuria following semaglutide-associated weight loss
Journal of nephrology, 2026
Suitability of the ICH S1B(R1) Weight-of-Evidence Framework to Evaluate Glucagon-Like Protein-1 Receptor Agonist (GLP-1RA) Carcinogenicity Risk
Regulatory toxicology and pharmacology : RTP, 2026;:106252
Oral semaglutide vs DPP-4 inhibitors in reducing risk of cognitive impairment in elderly patients with HFpEF and obesity
Internal and emergency medicine, 2026
Incretin-based injectable strategies versus intensified insulin for treatment intensification and simplification in type 2 diabetes: a systematic review and meta-analysis
Journal of diabetes and metabolic disorders, 2026;25(2):270
Canonical and Non-Canonical Regulators of Lipid Metabolism in the Liver and the “Liver-Other Organs” Axes
International journal of molecular sciences, 2026;27(19)
Anti-Obesity Medications Versus Metabolic Bariatric Surgery as Pathways to Heart Transplant Eligibility in LVAD-Supported Patients: A Narrative Review
Journal of clinical medicine, 2026;15(19)